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Over recent decades, the number of available clinical practice
guidelines has grown enormously. These guidelines are increasingly
used in health-care systems throughout the world to improve the
quality of patient care, and this also applies to cancer care. Evidence-
based guidelines are seen by professionals, authorities, managers and
policy makers as powerful tools for achieving effective and efficient
care (Woolf et al, 1999). They are considered to be the ideal mediator
for bridging the gap between the growing stream of research findings
and actual clinical practice. Guidelines should meet specific quality
criteria to ensure good quality. Users should be confident that
potential biases inherent in guideline development have been
addressed appropriately and that the recommendations for practice
are both internally and externally valid, as well as feasible for practice
(AGREE (Appraisal of Guidelines Research and Evaluation) Colla-
borative Group, 2000). However, recent studies have reported that the
methodological quality of many guidelines is modest and is
heterogeneous between the different guidelines and different guide-
line programmes (Shaneyfelt et al, 1999; Grilli et al,2 0 0 0 ;L a c a s s eet al,
2001; Burgers et al, 2003a). Although clinical guidelines can provide a
solution to some of the important problems in patient care, there are
issues that need to be tackled before guidelines can achieve their full
potential (Grol, 2001a). We will start by outlining these problems, and
then we will present a set of criteria for high-quality guidelines
developed and validated by an international group of researchers and
guideline developers (the AGREE collaboration). Some cancer
guidelines (including those produced by the French National
Federation of Cancer Centres–FNCLCC the SOR) were used in the
validation process for these criteria. We will then provide some
recommendations for guideline developers with the aim that this will
help researchers and practitioners in cancer care to develop high-
quality guidelines for the management of their patients.
PROBLEMS WITH GUIDELINES
Various problems with guidelines and their development that can
impede their maximal use and profit have been reported:
Lack of quality: There are currently too many low-quality
guidelines. There seems to be a ‘guideline industry’ emerging in
many Western countries with a considerable variation in guide-
lines from different sources (Grol et al, 1998a). Physicians and
other professionals are probably overwhelmed by all these
guidelines, particularly since guidelines on the same topic some-
times present different recommendations for practice (Fahey and
Peters, 1996; Psaty and Furberg, 1999). Many of the current
guidelines have not been developed in a rigorous and systematic
way, and are not based on the best evidence or present the vested
interests of specific parties, including health-care industries. A
series of recent studies assessing the quality of clinical guidelines
show that many guidelines do not meet important quality criteria
(Ward and Grieco, 1996; Varonen and Ma ¨kela ¨ 1997; Cluzeau et al,
1999; Shaneyfelt et al, 1999; Grilli et al, 2000; Lacasse et al, 2001).
The unsystematic development of guidelines can contribute to this
low quality (Thomson et al, 1998; Burgers et al, 2003a).
Lack of evidence: A second problem is that despite a rigorous
search and analysis of the scientific literature, clear evidence is
available for only part of the practical actions and decisions
recommended in the guidelines (Vogel et al, 2000; Dinkevich et al,
2001). There is a large grey area where expert opinions,
practitioners’ and patients’ preferences as well as societal priorities
are more important in the development of guidelines than research
results (Naylor, 1995, Eccles et al, 1998). When evidence is missing,
reliable procedures for including expert opinions and stakeholders’
preferences are required; such procedures are not present in many
guideline development programmes (Burgers et al, 2003b).
Translation of evidence into recommendations for practice:E v e n
when evidence has been summarised, it is often difficult to translate it
into recommendations for practice. Guideline users deal with a more
heterogeneous population of patients and more complex health-care
processes than those covered in the original research (Van Weel and
Knottnerus, 1999; Koes et al, 2001). Most cancer clinical research
deals with separate diagnostic or treatment decisions in selected
samples of patients, while the practice of cancer care usually involves
dealing with complex multidisciplinary care processes in a variety of
patient groups. There has been very little research into the best way to
manage such processes and chains of related actions and decisions by
different care providers. Also, it is not easy to translate guideline
recommendations into decisions in practice, since guidelines can
never cover all the relevant clinical details necessary for individual
patients. Most guidelines fail to take these issues into account.
Interpretation of evidence: Guidelines are developed by humans
and the process is, therefore, prone to errors and subjective
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www.bjcancer.cominterpretations on the one hand and personal values and cultural
backgrounds on the other. Even when clear evidence is available, it
is often interpreted differently by different guideline developers in
different settings from different cultural or professional back-
grounds (Fahey and Peters 1996; Koes et al, 2001). For example,
the USA guidelines for the management of patients with high risk
of breast cancer recommend regular self-examination and
prophylactic mastectomy (requiring patient consent only). In
contrast, the French guidelines do not recommend self-examina-
tion (because this may induce fear) and are very strict with regard
to prophylactic mastectomy (Eisinger et al, 1999). The authors of
this study reported that evidence-based guidelines may be a result
of specific cultural beliefs.
Feasibility: The consequences of guidelines in terms of
acceptance by patients, and the resources, staff, skills and
equipment needed for implementation are usually not considered
during the development process. For example, in a study of a
structured method to educate patients with atrium fibrillation
about the benefits and risks of anticoagulation treatment, half of
the patients did not choose the evidence-based treatment (Howitt
and Armstrong, 1999). Another example is the implementation of a
dyspepsia guideline in the UK that may have resulted in a three-
fold increase in the number of endoscopies (Haycox et al, 1999).
Whether a society is willing and able to pay the bill for particular
innovations cannot be determined on the basis of scientific
evidence. Most guidelines do not consider these issues.
Difficult implementation: For a long time, most guideline
developers assumed that good evidence presented to practitioners
in a structured way automatically led to better performance.
However, results from many controlled trials and systematic
reviews show that efforts to implement guidelines are often not
very successful (Bero et al, 1998; Wensing et al, 1998; Grol and
Grimshaw, 1999; Grimshaw et al, 2001; Grol 2001b). At best, small
to moderate improvements in the care process have been found
(usually not more than 5–10%, depending on the implementation
methods used), whereas the impact on patient outcomes has often
not been studied or proved to be absent (Grimshaw and Russell,
1993; Hunt et al, 1998). Issues of implementation are seldom
addressed in the development of guidelines.
CRITERIA FOR GOOD-QUALITY GUIDELINES: THE
AGREE INSTRUMENT
To guarantee that clinical practice guidelines can be an effective
tool to improve care for (cancer) patients they should meet specific
quality criteria (Feder et al, 1999; Shekelle et al, 1999). This
concern is felt worldwide, and has been underlined by renewed
calls for internationally recognised standards to promote the
rigorous development of clinical guidelines and to assess their
quality (Shaneyfelt et al, 1999; Grilli et al, 2000). Clearly, these
standards should be valid, reliable and feasible.
The AGREE Collaboration has recently developed such criteria
in the context of an EU-funded research project. Bringing together
researchers and policy makers from 12 countries (UK, The
Netherlands, Denmark, Finland, France, Switzerland, Spain,
Canada, Italy, Germany, USA, New Zealand), the collaboration’s
aim is to establish comparable frameworks for the assessment and
monitoring of the quality of clinical practice guidelines, including
the process of development and the reporting of the process. The
AGREE Instrument was developed through a multistage process of
item generation, selection and scaling, field testing and refinement
procedures. A small working group first compiled a comprehen-
sive checklist of 82 items from existing appraisal instruments and
relevant literature that covered recognised components of guide-
line quality. The term ‘quality’ was defined as the confidence that
the biases linked to the rigour of development, presentation and
applicability of a guideline had been minimised during the
development process. Most of the items were derived from existing
lists or instruments (e.g. Lohr and Field, 1992; Grol et al, 1998b;
Cluzeau et al, 1999) to cover all aspects of the concept of quality.
Following preliminary testing, the checklist was reduced to 32
items classified into five quality domains. This was then circulated
to all the members of the AGREE collaboration and other
international experts for their comments. The resulting ‘first’
version of the instrument was then field tested for reliability and
validity on 100 guidelines with 195 appraisers from 11 countries,
with 31 cancer guidelines, including guidelines from the FNCLCC
and from the Canadian Cancer Care Ontario Practice Guidelines
Initiative. After refinement, the instrument was field tested again
on a random sample of 33 guidelines (including 14 cancer
guidelines) from the first field test with a new set of appraisers. The
results were encouraging and demonstrated that the instrument
was easy to use and could be applied consistently to a broad range
of guidelines across different countries (AGREE Collaboration,
2003). Generally, the scores for cancer guidelines were high with
the instrument (for example, they were higher than the scores for
guidelines on diabetes and asthma for rigour of development).
The final AGREE instrument consists of 23 key items (Table 1)
categorised into six domains (see: http://www.agreecollaboration.
org). Each domain is intended to measure a separate dimension of
guideline quality.
Scope and purpose (items 1–3): These items are concerned with
the overall aim of the guideline, the specific clinical questions and
the target patient population.
Stakeholder involvement (items 4–7): These items focus on the
extent to which the guideline represents the views of its intended
users. Guideline development needs to be carried out by a
multidisciplinary group involving all stakeholders whose clinical
activities are likely to be covered in the proposed guideline. This
also includes patient groups.
Rigour of development (items 8–14): These items relate to the
process used to gather and synthesise the evidence, and the
methods used to formulate the recommendations and to update
them. The recommendations should be explicitly linked to the
supporting evidence. However, because most current guidelines
use a mixture of ‘expert’ judgement and literature review,
disclosure of disagreement or uncertainties encountered during
the development may help to clarify the process. Guidelines should
be reviewed externally before publication, and the process used
clearly described. They should also always include a date of
publication, and because guidelines need to reflect current
research, they should contain a clear statement about the updating
procedures.
Clarity and presentation (items 15–18): These items deal with
the language and format of the guidelines. Since the main role of
guidelines is to help clinicians and patients make better decisions,
busy clinicians need simple, patient-specific, user-friendly guide-
lines that are easy to understand. Good guidelines present clear
information about the management options available and the
likely consequences of each. This information can be presented in
a variety of formats to suit the needs of the user.
Applicability (items 19–21): These items cover the likely
organisational, behavioural and cost implications of applying the
guidelines. Guidelines should be feasible to use in the current
organisation of care and must fit into routine practice and the time
constraints present. In addition, review criteria should be
developed that link the guideline use to audits and other quality
improvement initiatives.
Editorial independence (items 22–23): These items assess the
independence of the recommendations and acknowledgement of
possible conflict of interests for the members of the guideline
development group. An increasing number of guidelines are
funded directly, or indirectly, by external funding. There should be
an explicit statement that the views and/or interests of the funding
body have not influenced the final recommendations.
Clinical practice guidelines
R Grol et al
S5
British Journal of Cancer (2003) 89(Suppl 1), S4–S8 & 2003 FNCLCCTo help users understand the items, the instrument contains a
users’ guide with explanatory notes. Each item is scored on a reduced
four-point Likert scale, and there is an overall rating as to whether
the guideline should be recommended or not for use in practice.
The AGREE instrument was developed through a detailed and
lengthy process that took many years to complete. Despite this,
most of the AGREE quality criteria are still based on theoretical
assumptions rather than on empirical evidence. They were
developed through discussions between researchers from several
countries who have extensive experience and knowledge of clinical
guidelines. It remains to be shown that these criteria are actually
linked to ‘better’ quality guidelines leading to improved patient
care and outcomes. Another issue is that the AGREE instrument
relies heavily on the quality of the background documentation on
which the guidelines are based. Although defining quality by the
rigour of reporting rather than the rigour of content may not
provide information on the intrinsic quality of the guidelines, it is
clear that without some information about the development
process it is impossible to assess the quality of guidelines
(Hayward et al, 1995). Finally, guidelines need to be used if they
are to assist decision-making in practice. Our understanding of
what attributes of guidelines determine this complex process is
limited, although important research is emerging in the field (Grol
et al, 1998b; Foy et al, 2002). The quality of a guideline is affected
by scientific considerations as well as human and practical factors.
Future validation research will need to focus on how these
elements interact in clinical practice.
RECOMMENDATIONS FOR GUIDELINE DEVELOPERS
To ensure that guidelines are of high quality, they should be
preferably developed within a structured and coordinated guide-
lines programme (Table 2). A recent French ‘before–after’
controlled study confirmed the positive impact of the newly
established SOR guidelines programme on medical practice for
cancer management (Ray-Coquard et al, 2002). Sufficient budget
and resources are also needed (Shekelle et al, 1999). However,
substantial savings could be made by active cooperation between
national and international guideline organisations. This could
include the exchange of existing cancer guidelines and evidence
reports, collaboration for literature searches for revision of those
guidelines, and organising joint peer review of draft guidelines
(Browman, 2000). However, effective and efficient collaboration
requires that the methodological principles are common. The
development of the AGREE instrument, which involved the
participation of leaders from various guideline development
organizations, revealed an increased international consensus and
willingness to work together (Burgers et al, 2003b, AGREE
Collaboration, 2003). Recent programmes may benefit from the
methodology created by more established programmes. However,
it must also be kept in mind that each country has its own norms
and values that influence the content and presentation of
guidelines. Therefore, the aim should not be to develop interna-
tional guidelines, but to reach international agreement about the
requirements for methodology and reporting of guidelines (De
Maeseneer and Derese 1999). The AGREE instrument is an
excellent aid for improving the reporting of guidelines. For
instance, the Scottish Intercollegiate Guideline Network (SIGN)
provides a guide with examples derived from SIGN guidelines,
adjacent to each item, on how information can be made available
(SIGN50, 2001; http://www.sign.ac.uk). Uniform reporting gives a
certain guarantee of quality. Moreover, it simplifies the compar-
ison of guidelines for the same clinical conditions. For the
development (or revision) of guidelines, the use of existing high-
quality guidelines (for instance, guidelines included in the US
Table 1 The AGREE instrument
Scope and purpose
1. The overall objective(s) of the guideline is (are) specifically described.
2. The clinical question(s) covered by the guideline is (are) specifically described
3. The patients to whom the guideline is meant to apply are specifically described
Stakeholder involvement
4. The guideline development group includes individuals from all the relevant professional groups
5. The patients’ views and preferences have been sought
6. The target users of the guideline are clearly defined
7. The guideline has been piloted among target users
Rigour of development
8. Systematic methods were used to search for evidence
9. The criteria for selecting the evidence are clearly described
10. The methods for formulating the recommendations are clearly described
11. The health benefits, side effects and risks have been considered in formulating the recommendations
12. There is an explicit link between the recommendations and the supporting evidence
13. The guideline has been externally reviewed by experts prior to its publication
14. A procedure for updating the guideline is provided
Clarity and presentation
15. The recommendations are specific and unambiguous
16. The different options for management of the condition are clearly presented
17. Key recommendations are easily identifiable
18. The guideline is supported with tools for application
Applicability
19. The potential organisational barriers in applying the recommendations have been discussed
20. The potential cost implications of applying the recommendations have been considered
21. The guidelines present key review criteria for monitoring and/or audit purposes
Editorial independence
22. The guideline is editorially independent from the funding body
23. Conflicts of interest of guideline development members have been recorded
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(Baker and Feder, 1997; Adams et al, 1999; http://www.guideline.
gov/index.asp). For example, the literature search and review could
be used when similar questions are being examined. Above
all, it is useful to see how other guideline development groups
have collected and interpreted the evidence and how they have
translated the evidence into recommendations. After publication,
guidelines must be disseminated and implemented effectively
(Grol, 2001b). Guideline developers should be aware of the
potential facilitators for and barriers to implementation when
they are formulating the recommendations. If substantial
changes in practice are necessary to apply the recommendations,
additional information should be added with practical suggestions,
for example, about improved organisation of the care processes.
They should also pay particular attention to the format and
presentation of the guideline, for example, by providing
short summaries that can be easily used during contacts with
patients (Hayward et al, 1997; Jackson and Feder, 1998).
Furthermore, application tools should be developed, such as
indicators for performance assessment, teaching materials,
patient information pamphlets, or computer decision-aids. It is
important to involve the end users in the development process
to ensure local acceptance and relevance to local practice
(Browman, 2001).
A final, but important, consideration is the need to keep
guidelines up-to-date. Shekelle et al (2001a) presented a model
for assessing the validity of guidelines based on a combination
of multidisciplinary expert opinion and literature searches. The
use of recent systematic reviews can considerably limit the
workload of literature searching (Cook et al, 1997; Silagy et al,
2001). Based on a review of new evidence, the update may be
major or minor. It has been suggested that, in principle, the
update procedure should be performed every three years (Shekelle
et al, 2001b).
NEW DEVELOPMENTS
Clinical practice guidelines should meet specific quality criteria if
they are to be valuable tools in the care for cancer patients. These
criteria have been defined and validated by the AGREE Collabora-
tion (see Table 1). Better collaboration between guideline
developers throughout the world is important to avoid unneces-
sary duplication of effort. One such collaboration, the ‘Interna-
tional Guidelines Network (GIN–http://www.g-i-n.net/)’, is
currently being established and will be operational soon. Another
collaboration, specifically for cancer guidelines, is also being
prepared and will apply for funding under the European Union’s
6th Framework Programme. Such networks will provide a platform
for international information exchange and collaborative research.
These efforts will apply to existing guidelines or guidelines under
development, guidelines reviews, methodological information (for
example, a guide for guideline developers) and tools for
application and evaluation of guidelines. We expect that many
guideline organisations throughout the world will join the
proposed networks.
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